Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
442 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bone Marrow Transplant Rejection - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H2 2017, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape. Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 22, 12, 47, 9 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3, 14 and 2 molecules, respectively. Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology). - The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Bone Marrow Transplant Rejection - Overview 7 Bone Marrow Transplant Rejection - Therapeutics Development 8 Bone Marrow Transplant Rejection - Therapeutics Assessment 27 Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development 39 Bone Marrow Transplant Rejection - Drug Profiles 72 Bone Marrow Transplant Rejection - Dormant Projects 413 Bone Marrow Transplant Rejection - Discontinued Products 417 Bone Marrow Transplant Rejection - Product Development Milestones 418 Appendix 429
List of Tables
Number of Products under Development for Bone Marrow Transplant Rejection, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 Products under Development by Companies, H2 2017 (Contd..5), H2 2017 Products under Development by Universities/Institutes, H2 2017 Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by AbGenomics International Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Allergan Plc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Amunix Operating Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by AnaptysBio Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by apceth Biopharma GmbH, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Aptevo Therapeutics Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by arGEN-X BV, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Athersys Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Bio-Cancer Treatment International Ltd, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Biogen Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Bristol-Myers Squibb Company, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Capricor Therapeutics Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Cell Source Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Cell2B Advanced Therapeutics SA, H2 2017 Bone Marrow Transplant Rejection - Pipeline by CellECT Bio Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Cleveland BioLabs Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Commence Bio Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Compugen Ltd, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Cynata Therapeutics Ltd, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Cytodyn Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Escape Therapeutics Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Fate Therapeutics Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Generon (Shanghai) Corp Ltd, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Gilead Sciences Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by GlaxoSmithKline Plc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Heat Biologics Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Incyte Corp, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Jazz Pharmaceuticals Plc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Johnson & Johnson, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Kadmon Corp LLC, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Kamada Ltd, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Kiadis Pharma NV, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Kymab Ltd, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017 Bone Marrow Transplant Rejection - Pipeline by MacroGenics Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Mallinckrodt Plc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Mesoblast Ltd, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Nohla Therapeutics Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Novartis AG, H2 2017 Bone Marrow Transplant Rejection - Pipeline by OncoImmune Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Pfizer Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Pharmicell Co Ltd, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Pluristem Therapeutics Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by REGiMMUNE Corp, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Sanofi, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Sarepta Therapeutics Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Seattle Genetics Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Seres Therapeutics Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Sigmoid Pharma Ltd, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Synedgen Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Taiga Biotechnologies Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Targazyme Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by TC BioPharm Ltd, H2 2017 Bone Marrow Transplant Rejection - Pipeline by TxCell SA, H2 2017 Bone Marrow Transplant Rejection - Pipeline by United BioPharma Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Vault Pharma Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by VBI Vaccines Inc, H2 2017 Bone Marrow Transplant Rejection - Pipeline by Xenikos BV, H2 2017 Bone Marrow Transplant Rejection - Pipeline by XL-protein GmbH, H2 2017 Bone Marrow Transplant Rejection - Pipeline by ZIOPHARM Oncology Inc, H2 2017 Bone Marrow Transplant Rejection - Dormant Projects, H2 2017 Bone Marrow Transplant Rejection - Dormant Projects, H2 2017 (Contd..1), H2 2017 Bone Marrow Transplant Rejection - Dormant Projects, H2 2017 (Contd..2), H2 2017 Bone Marrow Transplant Rejection - Dormant Projects, H2 2017 (Contd..3), H2 2017 Bone Marrow Transplant Rejection - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
